Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

20161,764 citationsJournal Articlebronze Open Access

Authors

Brian G. Feagan · Western University

William J. Sandborn · Western University

Christopher Gasink · Western University

Douglas Jacobstein · Western University

Yinghua Lang · Western University

Joshua R. Friedman · Western University

Marion Blank · Western University

Abstract

Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.

Topics & Keywords

Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 20, pp. 1946-1960

DOI: 10.1056/nejmoa1602773

Field-Weighted Citation Impact: 143.79